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Dapagliflozin reduces albuminuria in patients with diabetes
and hypertension receiving renin-angiotensin blockers
H. J. L. Heerspink1, E. Johnsson2, I. Gause-Nilsson2, V. A. Cain3 & C. D. Sjöström2
1University of Groningen, University Medical Center, Groningen, The Netherlands
2AstraZeneca, Gothenburg, Mölndal, Sweden
3AstraZeneca, Wilmington, DE, USA
Aims: To characterize the effect of dapagliflozin on albuminuria and estimated glomerular filtration rate (eGFR) and to determine whether effects on
albuminuria were mediated through changes in glycated haemoblogin (HbA1c), systolic blood pressure (SBP), body weight or eGFR.
Methods: We conducted a post hoc analysis of data pooled from two phase III clinical trials in hypertensive patients with type 2 diabetes (T2DM)
on stable angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, randomly assigned to dapagliflozin 10mg/day or matched
placebo. This analysis included only patients with microalbuminuria or macroalbuminuria at baseline.
Results: Patients were randomized to receive dapagliflozin 10mg (n= 167) or placebo (n= 189). Dapagliflozin resulted in greater 12-week reductions in
albuminuria compared with placebo: −33.2% [95% confidence interval (CI) −45.4, −18.2]. The reduction in albuminuria was also present after adjusting
for age, sex and changes in HbA1c, SBP, body weight and eGFR: −23.5% (95% CI −37.6, −6.3). There was a decrease in eGFR with dapagliflozin versus
placebo that was readily reversed 1week after last dose. No serious renal-related adverse events were observed in any group.
Conclusions: Dapagliflozin was effective in lowering albuminuria in patients with T2DM and hypertension using renin-angiotensin system blockade
therapy. Reductions in albuminuria were still present after adjusting for changes in HbA1c, SBP, body weight and eGFR. Dapagliflozin-induced
improvements in glycaemic control and reductions in SBP, coupled with other potentially beneficial renal effects, may lead to a reduced long-term
renal and cardiovascular risk.
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Introduction
People with type 2 diabetes mellitus (T2DM) are at a high risk
of both cardiovascular and renal disease [1]. Known risk factors
for cardiovascular and renal disease include hyperglycaemia,
hypertension and albuminuria, and controlling these factors is
critical in order to reduce this risk [1]. Dapagliflozin, a highly
selective sodium-glucose co-transporter 2 (SGLT2) inhibitor,
has been shown to improve glycaemic control by decreasing
renal glucose reabsorption in the kidneys and increasing uri-
nary glucose excretion [2–4]. In addition to improving gly-
caemic control, dapagliflozin has been shown to have beneficial
effects on bodyweight, blood pressure and other cardiovascular
risk factors [5–7].
Evidence suggests that SGLT2 inhibition may also confer
renoprotective effects [8,9]. The underlying potential renopro-
tective mechanism of SGLT2 inhibition may be explained by
enhanced tubulo-glomerular feedback, leading to a reduction
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in intraglomerular pressure and an accompanying acute fall in
estimated glomerular filtration rate (eGFR) [10–12]. Addition-
ally, experimental studies have suggested that treatment with
SGLT2 inhibitors results in a reduction of intrarenal inflamma-
tion [13], similar to that seenwith angiotensin receptor blockers
(ARBs) [14], and may also exert additive anti-inflammatory
effects when combined with angiotensin-converting enzyme
(ACE) inhibitors [15]. Conversely, a recent animal model
study did not show any renal-specific effect apart from
glucose-lowering with SGLT2 inhibitor treatment [16].
Given the divergent preclinical findings, we first character-
ized in a clinical setting the effect of dapagliflozin on albu-
minuria and eGFR in patients with T2DM, hypertension and
microalbuminuria or macroalbuminuria, and second, inves-
tigated whether any observed changes in albuminuria were
dependent or independent of changes in glycated haemoglobin
(HbA1c), systolic blood pressure (SBP), body weight or eGFR.
Methods
Study Design
This was a post hoc analysis of data pooled from two multi-
centre, randomized, double-blind, parallel, placebo-controlled
phase III trials, conducted during 2010–2013, that evaluated the
efficacy and safety of dapagliflozin in patients with T2DMwith
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inadequately controlled hypertension despite receiving ACE
inhibitor or ARB therapy (NCT01137474, NCT01195662).The
trial designs comprised a qualification period (≤14 days fol-
lowing enrolment), a lead-in period (4weeks), a double-blind
treatment period (12weeks) and a follow-up period (1week).
The study protocols were approved by the institutional review
board/independent ethics committee at each site and all
patients provided written informed consent. The trials were
conducted according to the principles of the Declaration of
Helsinki. Detailed descriptions of the methods and primary
results of the two trials have been published [17,18].
Eligibility Criteria
Patients included in this analysis met the following criteria:
18–89 years of agewith inadequately controlled T2DM[defined
as HbA1c 7.0–10.5% (53–91mmol/mol)]; inadequately con-
trolled hypertension (defined as seated SBP 140–165mmHg
and seated diastolic blood pressure 85–105mm Hg); and albu-
minuria [defined as urine albumin/creatinine ratio (UACR)
≥30mg/g]. All patients were required to be taking a stable dose
of an oral antidiabetic drug (OAD) for ≥6weeks (12weeks for
thiazolidinediones) or insulin (monotherapy or in combina-
tion with an OAD) for 8weeks, and a stable dose of an ACE
inhibitor or an ARB for ≥4weeks. Patients with a C-peptide
level ≥0.8 ng/ml (0.3 nmol/l), a body mass index ≤45.0 kg/m2,
and serum creatinine <1.50mg/dl (114.4 μmol/l) for men or
<1.40mg/dl (106.8 μmol/l) for women were included. Patients
with an estimated creatinine clearance <60ml/min were
excluded.
Randomization and Treatment
After a 4-week placebo lead-in, patients were randomized using
an interactive voice response system in a 1 : 1 ratio to receive
dapagliflozin 10mg or placebo once daily for 12weeks. Ran-
domization was stratified by additional antihypertensive medi-
cation use and/or insulin use at baseline.
Outcome Measures
The main endpoints in the present analysis were changes from
baseline to week 12 in UACR and changes from baseline to
1week after treatment cessation for eGFR. UACR was derived
from a single spot urine sample. Urinary albumin and urinary
creatinine concentration were measured in a central laboratory
(Quintiles Laboratories, Marietta, GA, USA; Livingston, UK;
Mumbai, India; or Mexico City, Mexico). eGFR was calculated
using the modification of diet in renal disease formula [19].
Changes from baseline in UACR to week 12 were also exam-
ined after controlling for changes in HbA1c, SBP, body weight
and eGFR.
Safety assessments were performed during the double-blind
treatment period plus 4 days post-dose for non-serious
adverse events (AEs) and 30 days post-dose for serious AEs.
Safety outcomes also included discontinuations attributable
to AEs, AEs of special medical interest and laboratory
abnormalities.
Statistical Analysis
Descriptive statistics were used to describe the baseline char-
acteristics and safety of patients in the pooled analysis of these
trials.
The UACR values were log-transformed and analysed with
a longitudinal repeated-measures mixed model using direct
likelihood, with fixed categorical effects of treatment, week,
treatment-by-week interaction and study, and continuous
covariates of baseline and baseline-by-week interaction in the
model. The influence of other covariates on changes in UACR
was explored by adding continuous fixed covariates of change
from baseline to week 12 in HbA1c, SBP, body weight and
eGFR to the model. In addition, age and gender were added
to the model. Changes in HbA1c, eGFR, body weight and SBP
were analysed with a longitudinal repeated-measures mixed
model using direct likelihood, with fixed categorical effects
of treatment, week, treatment-by-week interaction, study
and continuous covariates of baseline and baseline-by-week
interaction in the model.
To further characterize the impact of the individual variables
on the overall change in UACR, an additional post hocmultiple
regression analysis was performed on only patients completing
the 12-week study period. By imputing representative mean
changes versus placebo for HbA1c, SBP, body weight and eGFR
in addition to treatment assignment into this model, estimates
for the contribution of the individual components to the overall
change in UACR were received.
Finally, data from the dapagliflozin-treated patients were
explored in an analysis of HbA1c and SBP responders/
non-responders to further examine the effect of these variables
on UACR. An HbA1c or SBP responder was defined as a
patient in the dapagliflozin treatment arm with a 12-week
HbA1c or SBP change lower than the median; a non-responder
was defined as a patient in the dapagliflozin treatment arm
with a 12-week HbA1c or SBP change on or above the median.
The model included study, baseline, responder (yes/no) and
study-by-baseline interaction.
All analyses were performed with SAS/STAT v.8.2 or higher
(SAS Institute Inc., Cary, NC, USA).
Results
Disposition and Baseline Characteristics
Of 1062 patients randomized to receive dapagliflozin 10mg or
placebo in the two original studies, a total of 356 patients with a
UACR≥30mg/g at baseline and at least one post-baselinemea-
surement in the double-blind treatment period were included
in this analysis (placebo, n= 189; dapagliflozin, n= 167). The
baseline demographics, clinical and biochemical characteristics
were generally similar between the treatment groups (Table 1).
The mean age of patients was 55 (20–74) years. The durations
of hypertension and of T2DM were ∼8 years, and the majority
of patients (∼75%) had microalbuminuria.
Effect of Dapagliflozin on Albuminuria and Estimated
Glomerular Filtration Rate
Patients receiving dapagliflozin 10mg had a median (25th,
75th percentile) UACR of 75.0mg/g (44.0, 267.0) at baseline,
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n= 189 n= 167
Male, % 69.8 57.5






BMI, kg/m2 31.3± 5.2 31.6± 5.6
HbA1c, mmol/mol (%) 65± 9.8 (8.1± 0.9) 65± 10.9 (8.1± 1.0)
Diabetes duration, years 8.3± 5.9 8.6± 6.5
Microalbuminuria, n (%)* 140 (74.1) 128 (76.6)
Macroalbuminuria, n (%)† 49 (25.9) 39 (23.4)
UACR, mg/g (median,
25th, 75th percentile)
78.0 (44.0, 267.0) 75.0 (44.0, 267.0)
eGFR, ml/min/1.73m2 85.8± 21.0 82.1± 19.7
SBP, mmHg 151.4± 8.0 151.9± 9.0
DBP, mmHg 91.5± 5.2 91.3± 5.1
Hypertension duration,
years
7.4± 6.7 8.1± 7.2
All data are mean± standard deviation unless otherwise stated.
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated
glomerular filtration rate; HbA1c, glycated haemoglobin; SBP, systolic
blood pressure; UACR, urine albumin/creatinine ratio.
*Microalbuminuria was defined as UACR ≥30 to <300mg/g.
†Macroalbuminuria was defined as UACR ≥300mg/g.
which was reduced to 47.5mg/g (23.5, 177.0) after 4weeks
of treatment and remained stable ending at 50.0mg/g (23.0,
148.0) at 12weeks. In patients treated with placebo, UACR
decreased from 78.0mg/g (44.0, 267.0) at baseline to 66.0mg/g
(32.0, 203.0) at 4 weeks and 74.0mg/g (38.0, 181.0) at week 12.
Relative to placebo, dapagliflozin significantly decreased albu-
minuria by −33.2% (95% CI −45.4, −18.2) after the 12-week
follow-up (Figure 1A). Changes in UACR of a similar magni-
tude were observed in patients with baselinemicroalbuminuria
−35.4% (95% CI −48.8, −18.7) or macroalbuminuria [−28.3%
(95% CI −52.9, 9.2)]. The proportions of patients with at least
a 30% reduction in albuminuria at week 12 were 49.7 and
37.4% in the dapagliflozin and placebo groups, respectively.
The corresponding proportions of patients who improved from
macroalbuminuria or microalbuminuria categories to a lower
category (microalbuminuria or normoalbuminuria) were 40.5
and 23.9%, respectively.
Baseline eGFR was 82.1 and 85.8ml/min/1.73m2 in the
dapagliflozin and placebo groups, respectively. An initial
decrease in eGFRwas observed in the dapagliflozin group at the
start of treatment (Figure 1B). At week 4, reductions in eGFR
(ml/min/1.73m2) were −4.8ml/min/1.73m2 (95% CI −6.7,
−3.0) in the dapagliflozin group and −1.3ml/min/1.73m2
(95% CI −3.1, 0.4) in the placebo group. eGFR remained lower
in the dapagliflozin group during the 12-week follow-up, with
a difference from placebo at week 12 of −2.80ml/min/1.73m2
(95% CI −5.43, −0.16; Figure 1B). The initial reduction in
eGFR in the dapagliflozin group was completely reversible after
treatment discontinuation. At the 1-week follow-up visit after
treatment discontinuation, eGFRwas 0.7ml/min/1.73m2 (95%
CI −1.4, 2.7) higher relative to baseline in the dapagliflozin
group and −0.9ml/min/1.73m2 (95% CI −2.8, 1.1) lower
relative to baseline in the placebo group.
Effect of Dapagliflozin on Glycated Haemoglobin, Blood
Pressure and Body Weight
At week 12, patients receiving dapagliflozin had
placebo-corrected changes in HbA1c and SBP of −0.5%
(95% CI −0.7, −0.3) and −3.5mmHg (95% CI −5.9, −1.0),
respectively (Figure 2). The corresponding change in body
weight was −0.76 kg (95% CI −1.27, −0.26).
Albuminuria-lowering Effect Independent of Changes
in Glycated Haemoglobin, Blood Pressure, Body Weight
and Estimated Glomerular Filtration Rate
To assesswhether the effect of dapagliflozin on albuminuriawas
mediated by changes in HbA1c, SBP or eGFR, the main analy-
sis was repeated with adjustments for age, gender and changes
in HbA1c, SBP, body weight and eGFR. The placebo-corrected
change in UACR at week 12 was −23.5% (95% CI −37.6, −6.3)
for dapagliflozin, suggesting that the albuminuria-lowering
effect was still present after accounting for changes in HbA1c,
SBP, body weight and eGFR and was to a large extent indepen-
dent of changes in these covariates.
In two different post hoc analyses the impact of the dif-
ferent variables on change in UACR was further explored.
First, a regression analysis in patients completing the 12-week
study was conducted in which the proportion of the effect
explained by HbA1c, SBP, body weight and eGFR changes was
quantified. When imputing mean changes versus placebo of
−0.5% (HbA1c),−3.5mmHg (SBP),−0.8 kg (bodyweight) and
−2.8ml/min/1.73m2 (eGFR), this analysis (overall regression:
p< 0.0001, r2 = 11.5%) indicated that the effect of dapagliflozin
on albuminuria after 12weeks of treatment was to a large extent
independent of changes in HbA1c, SBP, body weight or eGFR
(Figure 3). Further adjustment for baseline age or gender did
not alter this finding. Furthermore, a second post hoc anal-
ysis in which dapagliflozin-treated patients were stratified by
the median value for 12-week changes in HbA1c and SBP
showed that the albuminuria-lowering effect of dapagliflozin
was present in both subgroups (Figure 2).
Safety
Overall, dapagliflozin was well tolerated with no increase in
AEs leading to study drug discontinuation (Table 2). The fre-
quency of AEs potentially related to volume depletion, uri-
nary tract or genital infections and renal function was low;
however, there were small numerical increases in these AEs in
dapagliflozin-treated patients as compared with placebo. None
of these events was classified as serious. Similar proportions of
patients between the two treatment groups experienced abnor-
mal laboratory values (defined as increases in serum creatinine
≥1.5× baseline or potassium ≥6mEQ/l).
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Figure 1. Change in (A) urine albumin/creatinine ratio (UACR) and (B) estimated glomerular filtration rate (eGFR) over time. Error bars represent 95%
confidence interval (CI). ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; DAPA, dapagliflozin; PBO, placebo.
Discussion
This post hoc analysis studied the effects of dapagliflozin as
an adjunct to ACE inhibitors and ARBs on renal variables in
patients with T2DM and microalbuminuria or macroalbu-
minuria. Treatment with dapagliflozin reduced albuminuria
compared with placebo and caused an initial fall in eGFR
that was completely reversible 1week after study drug discon-
tinuation. The albuminuria-lowering effect of dapagliflozin
was to a large extent independent of the HbA1c-, SBP-, body
weight- and eGFR-lowering effects, suggesting that other
mechanisms are also involved in the albuminuria-lowering
effect of dapagliflozin. These results also suggest that SGLT2
inhibition with dapagliflozin may confer renoprotective
effects.
An initial fall in glomerular filtration rate (GFR) has been
previously shown after administration of dapagliflozin [20]. In
the present study, however, we showed that the initial fall in
eGFR was completely reversible only 1week after dapagliflozin
discontinuation. This reversibility indicates that the initial
fall in eGFR did not reflect a reduction in the number of
functioning nephrons but a haemodynamic-induced reduction
in single nephron GFR. Indeed, SGLT2 inhibition increases
sodium delivery to the macula densa. The increased sodium
delivery is sensed as an increase in circulating volume at the
level of the juxtaglomerular apparatus, leading to a constriction
of afferent renal arterioles, a reduction in intraglomerular pres-
sure and a reversible reduction in single nephron GFR [10,21].
This reversible fall in eGFR is similar to that observedwith ACE
inhibitors and ARBs; however, the underlying mechanism is
different from that of SGLT2 inhibitors, as ACE inhibitors and
ARBs cause a vasodilatory efferent response, thereby decreas-
ing intraglomerular pressure. Various studies have shown that
a reduction in intraglomerular pressure is associated with
long-term renal preservation [22–24], suggesting that the
Volume 18 No. 6 June 2016 doi:10.1111/dom.12654 593
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Figure 2. (A) Effect of dapagliflozin versus placebo on glycated haemoglobin (HbA1c) and effect of dapagliflozin on urine albumin/creatinine ratio (UACR)


































Figure 3. Effect of dapagliflozin versus placebo on albuminuria and pro-
portion of effect mediated by changes in glycated haemoglobin (HbA1c),
systolic blood pressure (SBP), body weight (BW) and estimated glomerular
filtration rate (eGFR).
reversible fall in eGFR with dapagliflozin is an indicator of its
potential long-term renal protective potency.
Dapagliflozin also significantly decreased albuminuria.
This finding is consistent with other studies showing that
SGLT2 inhibitors decrease albuminuria [25,26]. In patients
with T2DM and chronic kidney disease (CKD), canagliflozin
100mg/day and empagliflozin 25mg/day decreased albu-
minuria by ∼22 and 35% relative to placebo, respectively
[25,26]. A principal finding of the present study is that the
albuminuria-lowering effect of dapagliflozin is to a large extent
independent of changes in eGFR, SBP, body weight or HbA1c.
Apparently, other effects of dapagliflozin account for the
albuminuria-lowering properties, although we cannot exclude
residual confounding caused by measurement variability. Con-
tinuous glucose excretion and the resulting metabolic effects
not measured in this study may be one explanation for the
potential renoprotective effects. Additionally, experimental
studies have suggested that SGLT2 inhibitors exert intrarenal
anti-inflammatory effects that may be mediated by inhibition
of glucose entry into tubular cells [13,27]. Anti-inflammatory
594 Heerspink et al. Volume 18 No. 6 June 2016
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Number of patients, % n= 189 n= 167
Overall safety summary
≥1 AE 87 (46.0) 81 (48.5)
AE leading to study drug
discontinuation*
2 (1.1) 2 (1.2)
≥1 serious AE 0 6 (3.6)









AEs of special interest
Renal events 3 (1.6) 5 (3.0)
Blood creatinine
increased
1 (0.5) 4 (2.4)
GFR decreased 1 (0.5) 1 (0.6)
Renal impairment 1 (0.5) 0
Volume reduction events 0 2 (1.2)
Hypovolaemia 0 1 (0.6)
Orthostatic hypotension 0 1 (0.6)
Infections
Urinary tract infection 3 (1.6) 6 (3.6)




4 (2.2) 4 (2.4)
Serum creatinine ≥1.5×
baseline value
2 (1.1) 2 (1.2)
ACE, angiotensin-converting enzyme; AE, adverse event; ARB, angiotensin
receptor blocker.
*Only hypoglycaemia reported as a serious AE was included as an AE,
serious AE, or AE leading to discontinuation.
interventions have indeed been linked with albuminuria
reduction [28]. Unfortunately, inflammatory biomarkers were
not measured in this study, and it is therefore not possible to
verify this possibility.
The finding that the albuminuria-lowering effect of
dapagliflozin was independent of changes in HbA1c or
SBP suggests a dissociation of the albuminuria response from
responses in HbA1c or SBP. This uncoupling of responses in
multiple characteristics of a single drug has also been observed
with other drugs including ACE inhibitors, ARBs, dipeptidyl
peptidase-4 inhibitors and endothelin receptor antagonists
[29–31]. The underlying mechanisms of this uncoupling in
response are unknown and require further study.
In the placebo arm, albuminuria decreased by nearly 20%,
which is a larger placebo effect compared with other clin-
ical trials [28,32,33]. The reduction in albuminuria in the
placebo arm probably reflects a regression to the mean phe-
nomenon, as we selected only patients with UACR ≥30mg/g
based on the value from a single visit; therefore, it is partic-
ularly important to interpret the albuminuria reduction with
dapagliflozin in the context of the placebo effect. Nevertheless,
this still resulted in a reduction of >30% after 12weeks of
treatment. The placebo-corrected reduction in albuminuria in
the dapagliflozin arm would translate into a 30% relative risk
reduction in end-stage renal disease, assuming no changes in
other renal risk markers [34].
As SGLT2 inhibition has been shown to increase urinary
glucose excretion and reduce eGFR, there have been con-
cerns around renal safety. There have also been concerns of
unfavourable volume loss attributable to the diuretic action. In
the present analysis in patients with albuminuria and a renal
function mainly within CKD stage 1 and 2 categories, there
were numerically more laboratory-associated AEs related to
renal function with dapagliflozin than with placebo, mainly as
a result of increases in blood creatinine. This was an expected
finding, given dapagliflozin’smode of action. Importantly, none
of these events was classified as serious by the investigators.
There was also no increase in the proportion of patients with
more pronounced creatinine increases (≥1.5× baseline values)
as compared with placebo. The proportion of patients with
a marked increase in serum potassium was also similar to
placebo. Although there were more patients with potentially
volume-related AEs as compared with placebo, none of these
AEs was classified as serious. As observed in previous stud-
ies, more patients receiving dapagliflozin experienced a urinary
tract infection, although the total number was low. Overall, this
post hoc analysis indicated a beneficial renal profile in the stud-
ied CKD categories.
The present study has some limitations that should be
taken into consideration. First, this was a post hoc analysis
of two randomized controlled trials, and the original stud-
ies were not designed to assess the effect of dapagliflozin
on renal variables. The results can therefore only be inter-
preted as hypothesis-generating. The study did not include
an active comparator to prospectively determine whether the
albuminuria-lowering effects were independent of glucose or
blood pressure control. A study design with two additional
treatment arms including a sulphonylurea derivative to control
HbA1c and hydrochlorothiazide to control blood pressure
could add to the interpretation. UACR was measured in a
single spot urine sample. It is known that the day-to-day
variability in spot urine samples is larger than first morning
void samples. The use of single spot urine samples in the
present study may have resulted in a lower precision (larger
standard error) of the treatment effect compared with when
first morning void samples were used; however, despite the
use of single spot urine samples, a clear and highly significant
treatment effect could still be detected. Finally, renal blood
flow and filtration fraction were not measured to determine
with ‘gold-standard’ techniques the effect of dapagliflozin on
intraglomerular pressure. The lack of measured GFR and use
of eGFR, which is less accurate, may explain why the effect
of dapagliflozin on albuminuria was not mediated by changes
in GFR.
In conclusion, reductions in albuminuria in patients with
T2DM and hypertension using renin-angiotensin system
blockade therapy were larger in dapagliflozin-treated patients
compared with placebo-treated patients.The reduction in albu-
minuria appeared to be in large part independent of changes
Volume 18 No. 6 June 2016 doi:10.1111/dom.12654 595
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in HbA1c, SBP, body weight or eGFR. The safety profile of
dapagliflozin in the present study was consistent with other
dapagliflozin studies and no increase in the occurrence of
serious renal AEs was observed. Improved glycaemic control
and reductions in SBP and body weight with dapagliflozin
treatment, in addition to beneficial renal effects, may alter
the course of progressive diabetic kidney disease and warrant
further study.
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